title: Pyrimidine ribonucleotides with enhanced selectivity as P2Y(6) receptor agonists: novel 4-alkyloxyimino, (S)-methanocarba, and 5'-triphosphate gamma-ester modifications.
abstract: The P2Y(6) receptor is a cytoprotective G-protein-coupled receptor (GPCR) activated by UDP (EC(50) = 0.30 microM). We compared and combined modifications to enhance P2Y(6) receptor agonist selectivity, including ribose ring constraint, 5-iodo and 4-alkyloxyimino modifications, and phosphate modifications such as alpha,beta-methylene and extension of the terminal phosphate group into gamma-esters of UTP analogues. The conformationally constrained (S)-methanocarba-UDP is a full agonist (EC(50) = 0.042 microM). 4-Methoxyimino modification of pyrimidine enhanced P2Y(6), preserved P2Y(2) and P2Y(4), and abolished P2Y(14) receptor potency, in the appropriate nucleotide. N(4)-Benzyloxy-CDP (15, MRS2964) and N(4)-methoxy-Cp(3)U (23, MRS2957) were potent, selective P2Y(6) receptor agonists (EC(50) of 0.026 and 0.012 microM, respectively). A hydrophobic binding region near the nucleobase was explored with receptor modeling and docking. UTP-gamma-aryl and cycloalkyl phosphoesters displayed only intermediate P2Y(6) receptor potency but had enhanced stability in acid and cell membranes. UTP-glucose was inactive, but its (S)-methanocarba analogue and N(4)-methoxycytidine 5'-triphospho-gamma-[1]glucose were active (EC(50) of 2.47 and 0.18 microM, respectively). Thus, the potency, selectivity, and stability of pyrimidine nucleotides as P2Y(6) receptor agonists may be enhanced by modest structural changes.
authors.affiliation: Molecular Recognition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Maruoka
authors.forename: Matthew O
authors.initials: MO
authors.lastname: Barrett
authors.forename: Hyojin
authors.initials: H
authors.lastname: Ko
authors.forename: Dilip K
authors.initials: DK
authors.lastname: Tosh
authors.forename: Artem
authors.initials: A
authors.lastname: Melman
authors.forename: Lauren E
authors.initials: LE
authors.lastname: Burianek
authors.forename: Ramachandran
authors.initials: R
authors.lastname: Balasubramanian
authors.forename: Barkin
authors.initials: B
authors.lastname: Berk
authors.forename: Stefano
authors.initials: S
authors.lastname: Costanzi
authors.forename: T Kendall
authors.initials: TK
authors.lastname: Harden
authors.forename: Kenneth A
authors.initials: KA
authors.lastname: Jacobson
mesh_terms: D045744:Cell Line, Tumor; D015226:Dinucleoside Phosphates / Q000737:chemistry* / Q000494:pharmacology*; D004952:Esters / Q000737:chemistry*; D006801:Humans; D007097:Imines / Q000737:chemistry*; D008958:Models, Molecular; D011122:Polyphosphates / Q000737:chemistry*; D011487:Protein Conformation; D058910:Purinergic P2 Receptor Agonists; D011743:Pyrimidines / Q000737:chemistry*; D018048:Receptors, Purinergic P2 / Q000737:chemistry; D012265:Ribonucleotides / Q000737:chemistry* / Q000494:pharmacology*; D013329:Structure-Activity Relationship; D013379:Substrate Specificity
chemical_list: D015226:Dinucleoside Phosphates; D004952:Esters; D007097:Imines; C000601171:P1-(5'-uridine)-P3-(5'-N4-methoxycytidine)triphosphate; D011122:Polyphosphates; D058910:Purinergic P2 Receptor Agonists; D011743:Pyrimidines; D018048:Receptors, Purinergic P2; D012265:Ribonucleotides; C099845:purinoceptor P2Y6; C030986:pyrimidine; C005692:triphosphoric acid
references.citation: Eur J Pharmacol. 2008 Jan 28;579(1-3):93-7
references.pmid: 18031728
references.citation: Purinergic Signal. 2005 Jun;1(2):183-91
references.pmid: 18404503
references.citation: Bioorg Med Chem. 2008 Jun 15;16(12):6319-32
references.pmid: 18514530
references.citation: J Med Chem. 2010 Jan 14;53(1):471-80
references.pmid: 19902968
references.citation: Cell Mol Neurobiol. 2003 Jun;23(3):401-18
references.pmid: 12825835
references.citation: Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):4034-9
references.pmid: 9108100
references.citation: Nature. 2007 Apr 26;446(7139):1091-5
references.pmid: 17410128
references.citation: Methods Enzymol. 2006;406:489-99
references.pmid: 16472681
references.citation: J Immunol. 2008 Feb 15;180(4):2659-68
references.pmid: 18250478
references.citation: J Med Chem. 2002 Jan 3;45(1):208-18
references.pmid: 11754592
references.citation: Biochem Pharmacol. 2010 May 1;79(9):1317-26
references.pmid: 20067775
references.citation: Drug Discov Today. 2010 Jul;15(13-14):570-8
references.pmid: 20594935
references.citation: J Pharmacol Exp Ther. 2002 Sep;302(3):871-80
references.pmid: 12183642
references.citation: Eur J Med Chem. 2009 Apr;44(4):1525-36
references.pmid: 18760862
references.citation: Bioorg Med Chem. 2009 Jul 15;17(14):5298-311
references.pmid: 19502066
references.citation: J Org Chem. 2008 Oct 17;73(20):8085-8
references.pmid: 18811198
references.citation: J Med Chem. 2004 Oct 21;47(22):5393-404
references.pmid: 15481977
references.citation: Pharmacol Res. 2008 Sep-Oct;58(3-4):232-9
references.pmid: 18805489
references.citation: Anal Biochem. 1976 May 7;72:248-54
references.pmid: 942051
references.citation: J Med Chem. 2005 Dec 29;48(26):8108-11
references.pmid: 16366591
references.citation: BMC Pharmacol. 2003 May 9;3:4
references.pmid: 12737633
references.citation: Pharmacol Rev. 2006 Sep;58(3):281-341
references.pmid: 16968944
references.citation: Purinergic Signal. 2008 Dec;4(4):365-75
references.pmid: 18784987
references.citation: J Med Chem. 2006 Nov 30;49(24):7076-87
references.pmid: 17125260
references.citation: Mol Pharmacol. 2008 Sep;74(3):777-84
references.pmid: 18523137
references.citation: J Biol Chem. 2005 Apr 29;280(17):16909-15
references.pmid: 15722352
references.citation: Eur J Pharmacol. 1997 Jun 25;329(2-3):231-6
references.pmid: 9226417
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2000 Nov;362(4-5):299-309
references.pmid: 11111825
references.citation: Mol Pharmacol. 2009 Dec;76(6):1341-8
references.pmid: 19759354
references.citation: J Mol Biol. 1966 Nov 28;21(3):405-19
references.pmid: 19768859
references.citation: J Med Chem. 2006 Sep 7;49(18):5532-43
references.pmid: 16942026
references.citation: Biochem Biophys Res Commun. 2008 Jun 6;370(3):499-503
references.pmid: 18387359